Cai Chun-Xia, Zheng Yong-Zhi, Wen Hong, Weng Kai-Zhi, Zhuang Shu-Quan, Wu Xing-Guo, LE Shao-Hua, Zheng Hao
Department of Pediatric Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fuzhou 350001, Fujian Province, China.
Department of Pediatric, The First Affiliated Hospital of Xiamen University, Xiamen 361000, Fujian Province, Chin.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Dec;32(6):1656-1664. doi: 10.19746/j.cnki.issn.1009-2137.2024.06.005.
To analyze the related factors of treatment failure in children with acute lymphoblastic leukemia (ALL) in real-world.
The clinical data of 1414 newly diagnosed children with ALL admitted to five hospital in Fujian province from April 2011 to December 2020 were retrospectively analyzed. Treatment failure was defined as relapse, non-relapse death, and secondary tumor.
Following-up for median time 49.7 (0.1-136.9) months, there were 269 cases (19.0%) treatment failure, including 140 cases (52.0%) relapse, and 129 cases (48.0%) non-relapse death. Cox univariate and multivariate analysis showed that white WBC≥50×10/L at newly diagnosis, acute T-cell lymphoblastic leukemia (T-ALL), , -rearrangement and poor early treatment response were independent risk factor for treatment failure (all HR>1.000, < 0.05). The 5-year OS of 140 relapsed ALL patients was only 23.8%, with a significantly worse prognosis for very early relapse (relapse time within 18 months of diagnosis). Among 129 patients died from non-relapse death, 71 cases (26.4%) were died from treatment-related complications, 56 cases (20.8%) died from treatment abandonment, and 2 cases (0.7%) died from disease progression. Among them, treatment-related death were significantly correlated with chemotherapy intensity, while treatment abandonment were mainly related to economic factors.
The treatment failure of children with ALL in our province is still relatively high, with relapse being the main cause of treatment failure, while treatment related death and treatment abandonment caused by economic factors are the main causes of non-relapse related death.
分析现实世界中急性淋巴细胞白血病(ALL)患儿治疗失败的相关因素。
回顾性分析2011年4月至2020年12月在福建省五家医院收治的1414例新诊断ALL患儿的临床资料。治疗失败定义为复发、非复发死亡和继发性肿瘤。
中位随访时间49.7(0.1 - 136.9)个月,有269例(19.0%)治疗失败,其中140例(52.0%)复发,129例(48.0%)非复发死亡。Cox单因素和多因素分析显示,初诊时白细胞(WBC)≥50×10⁹/L、急性T淋巴细胞白血病(T - ALL)、 重排以及早期治疗反应差是治疗失败的独立危险因素(均HR>1.000,P<0.05)。140例复发ALL患者的5年总生存率仅为23.8%,极早期复发(诊断后18个月内复发)患者的预后明显更差。在129例非复发死亡患者中,71例(26.4%)死于治疗相关并发症,56例(20.8%)死于放弃治疗,2例(0.7%)死于疾病进展。其中,治疗相关死亡与化疗强度显著相关,而放弃治疗主要与经济因素有关。
我省ALL患儿的治疗失败率仍相对较高,复发是治疗失败的主要原因,而治疗相关死亡和经济因素导致的放弃治疗是非复发相关死亡的主要原因。